Leerink downgraded Deciphera to Market Perform from Outperform with a price target of $25.60, down from $34, after Japanese pharma company Ono Pharmaceutical announced it would acquire Deciphera in an all-cash transaction for $25.60 per share. The firm notes that the boards of directors of both companies unanimously approved the transaction and it sees little risk of deal closure.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential